• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Infect Dis Performance of SARS-CoV-2 Antibody Assays in Different Stages of the Infection: Comparison of Commercial ELISA and Rapid Tests

tetano

Editor, Senior Moderator
Infect Dis


. 2020 May 30;jiaa305.
doi: 10.1093/infdis/jiaa305. Online ahead of print.
Performance of SARS-CoV-2 Antibody Assays in Different Stages of the Infection: Comparison of Commercial ELISA and Rapid Tests


M Traugott[SUP] 1 [/SUP], S W Aberle[SUP] 2 [/SUP], J H Aberle[SUP] 2 [/SUP], H Griebler[SUP] 2 [/SUP], M Karolyi[SUP] 1 [/SUP], E Pawelka[SUP] 1 [/SUP], E Puchhammer-St?ckl[SUP] 2 [/SUP], A Zoufaly[SUP] 1 [/SUP], L Weseslindtner[SUP] 2 [/SUP]



Affiliations

Abstract

We comparatively assessed sensitivities and specificities of four commercial ELISAs and two rapid tests in 77 patients with PCR confirmed SARS-CoV-2 infection, grouped by intervals since symptom onset. While test sensitivities were low (<40%) within the first 5 days post disease onset, IgM-, IgA- and total antibody-ELISAs increased in sensitivity to >80% between the 6th and 10th day post symptom onset. The evaluated tests (including IgG and rapid tests) provided positive results in all patients at or after the 11th day post onset of disease. Specificities of the ELISAs were 83% (IgA), 98% (IgG) and 97% (IgM and total antibodies).

Keywords: SARS; antibodies; coronavirus; immunoassay.
 
Back
Top Bottom